---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-039586"
form_type: "8-K"
ticker: "KAPA"
cik: "0001962011"
company_name: "Kairos Pharma, LTD."
filed_at: "2024-10-04T23:59:59+00:00"
generated_at: "2026-05-30T20:48:31.572884+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Kairos Pharma enters consulting pact with Cross Current for $700K total compensation

## Summary
- Consulting agreement for $200,000 cash and restricted shares valued at $500,000, subject to a six-month true-up to maintain $500K value.
- Shares cannot exceed 9.99% of outstanding common stock; vest after six months with possible additional 'true up' shares.
- Services include investor marketing, M&A canvassing, capital markets advisory; term is 24 months starting from NYSE American listing.
- Compensation and agreement effective upon listing (Start Date); registration statement on Form S-8 planned within 30 days after listing.

## SEC filing metadata
- accession: 0001493152-24-039586
- form_type: 8-K
- ticker: KAPA
- cik: 0001962011
- company_name: Kairos Pharma, LTD.
- filed_at: 2024-10-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1962011/000149315224039586/0001493152-24-039586-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1962011/000149315224039586/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-039586
- JSON: https://secwatch.observer/filing/0001493152-24-039586.json
- Plain text: https://secwatch.observer/filing/0001493152-24-039586.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.